Sažetak
Background: This study aimed to identify novel methylation-based prognostic biomarkers for endometrial cancer (EC) to facilitate early diagnosis and treatment. To explore methylation-related prognostic markers in endometrial tissue by analyzing TCGA data and to establish a methylation-based risk model for EC patients.
Materials and Methods: We systematically analyzed methylation-related gene expression and prognostic significance in 409 EC patients using TCGA DNA methylation data. DNA methylation biomarkers were identified through consensus clustering and weighted gene co-expression network analysis (WGCNA). The clusterProfiler algorithm was employed to determine key signaling pathways across different subgroups. A gene panel targeting critical DNA methylation sites was subsequently constructed.
Results: A methylation-related prognostic risk model was developed, incorporating five CpG sites: cg01416891, cg00082235, cg01493517, cg03811891, and cg05317207. The model demonstrated strong predictive performance, with high-risk patients exhibiting significantly poorer prognoses compared to low-risk patients. A gene panel was also established to predict prognosis across different EC risk groups.
Conclusion: The methylation-related gene panel model serves as a reliable prognostic biomarker for EC, offering potential for enhanced early diagnosis and personalized treatment strategies.
Ključne reči
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.